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Background: Screening for prostate cancer advances the
time of diagnosis (lead time) and detects cancers that would
not have been diagnosed in the absence of screening (over-
detection). Both consequences have considerable impact on
the net benefits of screening. Methods: We developed simu-
lation models based on results of the Rotterdam section of
the European Randomized Study of Screening for Prostate
Cancer (ERSPC), which enrolled 42 376 men and in which
1498 cases of prostate cancer were identified, and on baseline
prostate cancer incidence and stage distribution data. The
models were used to predict mean lead times, overdetection
rates, and ranges (corresponding to approximate 95% con-
fidence intervals) associated with different screening pro-
grams. Results: Mean lead times and rates of overdetection
depended on a man’s age at screening. For a single screening
test at age 55, the estimated mean lead time was 12.3 years
(range = 11.6–14.1 years) and the overdetection rate was
27% (range = 24%–37%); at age 75, the estimates were 6.0
years (range = 5.8–6.3 years) and 56% (range = 53%–61%),
respectively. For a screening program with a 4-year screen-
ing interval from age 55 to 67, the estimated mean lead time
was 11.2 years (range = 10.8–12.1 years), and the overdetec-
tion rate was 48% (range = 44%–55%). This screening pro-
gram raised the lifetime risk of a prostate cancer diagnosis
from 6.4% to 10.6%, a relative increase of 65% (range =
56%–87%). In annual screening from age 55 to 67, the es-
timated overdetection rate was 50% (range = 46%–57%)
and the lifetime prostate cancer risk was increased by 80%
(range = 69%–116%). Extending annual or quadrennial
screening to the age of 75 would result in at least two cases
of overdetection for every clinically relevant cancer detected.
Conclusions: These model-based lead-time estimates support
a prostate cancer screening interval of more than 1 year.
[J Natl Cancer Inst 2003;95:868–78]
Whether asymptomatic men benefit from screening for pros-
tate cancer is an unresolved question. Proponents of screening
point to the fact that screen-detected cancers tend to have a
favorable stage distribution (i.e., they are localized, and possibly
curable, cancers) compared with clinically diagnosed cancers
(1,2) and to decreasing prostate cancer mortality trends follow-
ing the introduction of prostate-specific antigen (PSA) screening
(3,4). Opponents of screening stress the fact that some men will
be treated unnecessarily, because they would not have been di-
agnosed with prostate cancer without screening. In addition,
opponents of screening suggest that the observed decrease in
prostate cancer mortality might be due to better treatments or to
misclassification of the cause of death (5–7). Moreover, they
note that decreasing prostate cancer mortality trends have been
registered in countries that do not have an active screening pro-
gram (8). However, the effect of screening on prostate cancer
mortality can only be established in a randomized clinical trial.
Two such trials have been initiated: the European Randomized
Study of Screening for Prostate Cancer (ERSPC) (9–11) and the
U.S. National Cancer Institute-sponsored Prostate, Lung, Colo-
rectal and Ovarian (PLCO) Cancer Screening Trial (12). Results
of those trials will not be available for several years.
Primary treatments for prostate cancer have adverse side ef-
fects. For example, among patients in the Rotterdam section of
the ERSPC who underwent radical prostatectomy after a pros-
tate cancer diagnosis, 80%–90% reported erectile dysfunction
and 39%–49% reported urinary incontinence (13). Among the
patients who underwent radiotherapy, 30%–35% reported bowel
problems, 41%–55% reported impotence, and 6%–7% reported
incontinence. Screening advances the time of diagnosis (lead
time) and detects cancers that would not have been diagnosed in
the absence of screening (overdetection). The impact of the ad-
verse effects of primary treatment in the total balance of costs
and benefits of screening will depend on the mean lead time and
the rate of overdetection due to PSA screening.
Mean lead times due to PSA screening have been estimated
in retrospective studies that used stored blood samples obtained
from individuals who were later clinically diagnosed with pros-
tate cancer; those estimates range from 5 to 10 years (14–17).
The possibility of overdetection is indicated by the large per-
centage (20%–50%, depending on age) of men who died without
prostate cancer symptoms but were found, at autopsy, to have
prostate tumors (18–20). The rate of overdetection can be ex-
pressed in several ways (Fig. 1). Zappa et al. (21) measured
overdetection as the estimated percent increase in the prostate
cancer incidence rate in Italy caused by biennial screening. Et-
zioni et al. (22) calculated the amount of overdetection in the
current PSA testing practice in the United States as a percentage
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of total detection by considering the probability of overdetection
to be equal to the probability of dying of other causes during the
lead time. Finally, McGregor et al. (23) defined overdetection as
the detection of nonlethal cancer.
We estimated mean lead times and overdetection rates asso-
ciated with several different PSA screening programs with the
simulation program MISCAN, an acronym for MIcrosimulation
SCreening ANalysis (24–26). MISCAN models were validated
against data from the Rotterdam section of the ERSPC trial,
which enrolled 21 166 men in the control (i.e., unscreened) arm
and 21 210 men in the screened arm and in which 1498 prostate
cancers were diagnosed.
SUBJECTS AND METHODS
ERSPC Trial, Rotterdam Section
The Rotterdam section of the ERSPC, one of eight partici-
pating centers in the ERSPC, was initiated in 1994 in the region
of Rotterdam and was approved by the Erasmus MC medical
ethics committee and the Dutch Ministry of Health (10). All men
in the Rotterdam region aged 55–74 years were identified with
the use of population registry data and invited to participate in
the trial. Men who completed and returned the written informed
consent form (response rate 49.2%) were randomly assigned to
the screened arm or to the control (i.e., unscreened) arm of the
trial. Prostate cancer cases among subjects in both arms of the trial
were identified through systematic record linkage to the Rotterdam
Cancer Registry. The Rotterdam Cancer Registry is part of the
Netherlands Cancer Registry, which started in 1989. The data
management office of the Rotterdam ERSPC center could access
the medical files of participants who provided written informed
consent to the study. In the January 2002 contribution of the
Rotterdam center to the central ERSPC database, follow-up was
considered complete up to July 2000 for subjects in both arms of
the trial. By July 2000, trial enrollment was completed, with
21 166 men in the control arm and 21 210 men in the screened
arm; 19 970 men (94%) in the screened arm had received a first
screening test and 3545 (18%) of these men had received a
second screening test. Two different screening protocols were
used over the course of the Rotterdam ERSPC. The first 9766
men assigned to the screening arm received a digital rectal ex-
amination (DRE), a transrectal ultrasound (TRUS), and a PSA
test. Those who had an abnormal DRE or TRUS, or whose
serum PSA level was least 4 ng/mL, were referred for a prostate
biopsy. (For the first 6894 men enrolled in the trial, the protocol
indicated an early recall visit after 1 year for those with a nega-
tive biopsy result. The early recall visits were later dropped from
the protocol.) The remaining 10 204 men invited for the first
round and all men invited for the second round received a PSA
test only; men who had a PSA level of 3 ng/mL or higher were
referred for a standard sextant biopsy of the prostate (27). The
recommended treatments for locally confined neoplasms were
radical prostatectomy or radiotherapy.
By July 1, 2000, 1075 cases of prostate cancer had been
detected in the first round of screening (including those found in
the early recall visits), and 143 cases had been detected in the
second round of screening. Only 23 cancers were diagnosed
outside the screening program among men in the screened arm
(interval cancers). A total of 221 prostate cancers were identified
among men in the control arm. Thirty-six cases could not be
classified because they never appeared for screening (n  17) or
they did not have a biopsy at the trial center following a positive
PSA test (n  19).
Basic MISCAN Prostate Cancer Model
MISCAN models are designed to evaluate cancer screening
programs (24–26). MISCAN models use a Markov process of
states and transitions to simulate and compare individual life
histories in the presence and in the absence of a cancer screening
program. Information about the epidemiology and natural his-
tory of the studied cancer, population characteristics, and screen-
ing modalities are used to set the key parameters of the model
(see next section).
For this study, we constructed a model of the development of
prostate cancer up to the time of detection by screening or clini-
cal diagnosis. In the model, prostate cancers were characterized
according to their stage and differentiation grade. Cancer stages
in the model were localized cancer [corresponding to Interna-
tional Union Against Cancer (UICC) (28) tumor–node–metasta-
sis (TNM) stages T1/2 N0/X M0/X], regional cancer (TNM
stages T3+ or N+ with M0/X), and distant cancer (any TN and
M1). The model distinguished three differentiation grades: Glea-
son score less than 7, Gleason score of 7, and Gleason score
more than 7. Thus, the model distinguished nine different pre-
clinical states. Screening was assumed to consist of a single
screening test with a sensitivity that depended on the stage of the
cancer. This simplification of the actual screening procedures
seemed justifiable because the two screening protocols used in
the ERSPC trial had similar detection rates (i.e., 55 cases per
1000 men screened for the initial protocol and 53 cases per 1000
men screened for the later protocol). A detailed description of
the basic MISCAN model for prostate cancer is provided in the
Appendix.
Fig. 1. Events in the natural history of prostate cancer and screening. All men are
screened (S). Some of these men develop screen-detectable preclinical cancer
(C1); a subset of C1 develops clinical cancer in the absence of screening (C2);
a subset of C2 dies of prostate cancer (C3). The men with screen-detected cancer
(D) are a subset of C1 and may be grouped into those who would not have been
diagnosed with prostate cancer in the absence of screening (D1), those who
would have been diagnosed with prostate cancer in the absence of screening but
would not have died of prostate cancer (D2), and those who would have died of
prostate cancer in the absence of screening (D3). The numbers represent the
probability (P) of each event (×1000), as predicted by the basic model. Question
marks indicate values that we have not estimated. The overdetection measures
used by Zappa et al. (21), Etzioni et al. (22), and McGregor et al. (23) are shown
at the lower right.
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Model validation. Table 1 lists the data used to validate the
model. Those data consisted of baseline (i.e., pre-screening) in-
cidence of prostate cancer in The Netherlands in 1991 (29),
baseline stage distribution of clinically diagnosed cancers [data
for 1992 and 1993, supplied by the Rotterdam Cancer Registry
(30)], and trial results up to July 1, 2000, including the number,
stage, and grade distribution of screen-detected cancers and in-
terval cancers among men in the screened arm and of cancers
diagnosed among men in the control arm. First-round results
included the cases detected during the early recall visits of the
initial screening protocol.
Excluded from the analysis were all cases diagnosed since
June 2000 (because of incomplete registry), cases diagnosed
before randomization (i.e., prevalent cases), 17 cases in men
who never appeared for screening, 10 cases in men older than
75 years, and 19 cases in men in the screened arm who had a
positive screen test (PSA 3 ng/mL or positive DRE or TRUS)
but did not undergo a biopsy at the trial center. Although most
of the latter cases should probably be considered screen-detected
cancers, we did not include them in this analysis because clas-
sification as screen-detected would not have affected results. We
did not have complete information about the distributions of
tumor stage and differentiation grade for 78 (35%) of 221 cases
identified in the control arm and for 52 (4%) of the 1218 screen-
detected cases, primarily because of missing Gleason scores;
tumor stage was missing for two cases in the control arm and for
13 cases in the screened arm. We used only cases for which
information was complete to fit stage and grade distribution in
the model.
For each set of model parameters (cumulative incidence, tran-
sition probabilities, duration parameters, test sensitivities), the
simulation model predicted the number of cases for each of the
categories listed in Table 1. Model parameters were estimated by
minimizing the difference between the observed and the pre-
dicted numbers of cancers as measured by the chi-square values
([observed – predicted]2/predicted). Details on parameter esti-
mation are given in the Appendix.
Variants of the basic model. We considered three variations
of the basic model, which is shown in Fig. 2. The first alternative
model included latent localized stage cancers (i.e., cancers with
a very slow rate of development but detectable by screening as
localized cancer), which would have had a negligible probability
of clinical diagnosis. Such a model was suggested by the high
detection rates in the trial (40–50 cases per 1000 men screened,
compared with an incidence of 3.2 cases per 1000 man-years in
the control arm). The second alternative model assumed that the
duration of preclinical cancer stages followed exponential dis-
tributions rather than Weibull distributions. In this simplified
model, the duration of the preclinical phase would have a larger
variance than in the basic model. In the third alternative model,
the differentiation grade (Gleason score) of a tumor could not
change once it had become detectable by screening. Because the
Gleason score is highly predictive for survival after treatment for
prostate cancer, we wanted to verify that our data could rule out
this possibility. All models were fit to baseline population data
and trial data jointly and, separately, to trial data only, to inves-
tigate whether (self-) selection of the trial population affected
trial results and our estimates of lead time and overdetection.
To correct for contamination, i.e., screening in the control
arm, we included such screening in all models as a yearly
screening test with a low attendance rate. In the models that were
fitted to both baseline and trial data, we estimated the contami-
nation rate jointly with the other model parameters. However, in
models that were fitted to trial data alone, we used an estimated
contamination rate of 20 tests per 1000 man-years (see Appen-
dix). This estimate is based on the percentage of cases presenting
without previous symptoms (30%). Assuming that these tests are
due to screening and that the detection rates are the same as
those in the screened arm, the contamination rate was calculated
as 17 tests per 1000 man-years (using the first-round detection
rate) or 22 tests per 1000 man-years (using the second-round
detection rate). The estimated rate of PSA testing in the control
arm was 71 tests per 1000 man-years (31), but the effective
screening rate is less than this, because some of the tests were
diagnostic tests rather than screening tests.
For all models, the goodness-of-fit is reported as the sum of
the chi-square values for the trial data only. The corresponding
P value was calculated with 42 degrees of freedom, which cor-
responded to the number of independent counts in the trial data
shown in Table 1, and assumed independence between age-
specific incidence or detection rates and the corresponding
stage-distribution data. These P values should be interpreted as
only approximate measures of the goodness-of-fit: the effective
number of degrees of freedom is certainly less than 42, because
the parameters that contributed to that number were estimated
from the data and because of possible dependence between in-
cidence and stage-distribution data.
Estimating prostate cancer overdetection rates and lead
times. We used the estimated natural history and screening pa-
rameters to simulate the effects of nine different screening pro-
grams on prostate cancer overdetection rates and lead times for
a hypothetical cohort of 1 million men. The nine screening pro-
grams were single-screen tests at age 55, 60, 65, 70, or 75 years;
annual screening from age 55 to 67; annual screening from age
55 to 75; screening at 4-year intervals, with tests at age 55, 59,
63, and 67 years; and screening at 4-year intervals, with tests at
age 55, 59, 63, 67, 71, and 75 years.
The simulations considered the life history of each cohort
member in the presence and absence of screening. Cancers de-
tected by screening were divided into two categories: relevant
cancers, which are cancers that would have been diagnosed
within the person’s lifetime in the absence of screening, and
irrelevant cancers, which are cancers that would not have been
diagnosed within the person’s lifetime in the absence of screen-
ing. Overdetection was defined as the detection of irrelevant
cancers. We calculated the amount of overdetection first as the
relative increase, caused by screening, of the number of men
with a cancer diagnosed during their lifetime, as in (21), and
second as the fraction of irrelevant cancers of all detected can-
cers, as in (22). Lead time was defined as the amount of time, in
years, between prostate cancer detection and either clinical di-
agnosis in the absence of screening or death by other causes. We
report the mean lead times for all screen-detected cancers and for
the screen-detected relevant cancers only. The first quantity
measures the number of years patients live with a cancer diag-
nosis; the second quantity allows comparisons, with lead times
estimated in retrospective studies.
We calculated 95% confidence intervals (CIs) for the mean
lead times associated with screening at ages 55, 59, 63, and 67
by using the profile likelihood approach detailed in the Appen-
dix. Because that approach was very computer intensive, instead
of repeating the procedure for the other outputs (lead times in
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Table 1. Model validation*
Observed Model prediction
n Incidence n Incidence
Baseline
Age group, y
Incidence per 1000 man-years† 45–50 11 0.02 24.55 0.05
50–55 58 0.14 66.35 0.16
55–60 131 0.36 165.80 0.46
60–65 387 1.19 368.34 1.13
65–70 734 2.59 694.98 2.45
70–75 950 4.50 947.44 4.49
75–80 969 6.57 985.53 6.68
80–85 668 7.98 696.96 8.33
>85 431 8.52 390.11 7.71
Trial target population 55–75 2202 1.86 2176.56 1.91
Stage distribution, %‡ Stage % %
(n  1637) Localized 58.03 57.71
Regional 18.81 19.44
Distant 23.15 22.85
Control arm
Age group, y
Incidence per 1000 man-years 55–60 22 1.51 12.83 0.88
60–65 29 1.59 34.03 1.87
65–70 70 4.11 63.25 3.71
70–75 80 5.96 82.35 6.13
>75 20 4.60 33.83 7.77
Trial target population 55–75 201 3.18 192.46 2.96
Stage and grade distribution, % Stage G<7 G  7 G>7 Total G<7 G  7 G>7 Total
(n  143) Localized 43.36 16.78 8.39 68.53 38.68 23.56 11.60 73.84
Regional 5.59 9.79 9.79 25.17 4.16 6.16 6.52 16.85
Distant 0.00 2.10 4.20 6.29 0.05 2.79 6.47 9.31
Total 48.95 28.67 22.38 100.00 42.89 32.51 24.60 100.00
Screened arm
Screening round 1 Screening round 2 Screening round 1 Screening round 2
n Rate n Rate n Rate n Rate
Age group, y
Detection rate per 1000 men screened 55–60 176 27.65 7 26.02 144.43 22.69 5.61 20.87
60–65 239 44.80 43 33.10 253.89 47.59 38.51 29.64
65–70 365 76.60 46 42.63 371.33 77.93 50.29 46.61
70–75 285 86.13 47 52.75 337.17 101.90 42.54 47.74
Trial target population 55–75 1065 53.86 143 40.42 1106.82 55.73 136.95 37.84
Stage and grade distribution of Round 1 (n  1034)
detected cancers, % Stage G<7 G  7 G>7 Total G<7 G  7 G>7 Total
Localized 56.96 17.41 4.45 78.82 57.12 17.31 4.23 78.66
Regional 7.93 9.77 2.90 20.60 8.01 9.73 3.05 20.79
Distant 0.00 0.10 0.48 0.58 0.00 0.08 0.47 0.55
Total 64.89 27.27 7.83 100.00 65.14 27.12 7.74 100.00
Round 2 (n  132)
Stage G<7 G  7 G>7 Total G<7 G  7 G>7 Total
Localized 75.76 16.67 1.52 93.94 76.30 11.15 2.95 90.39
Regional 1.52 3.03 1.52 6.06 4.33 4.09 1.09 9.52
Distant 0.00 0.00 0.00 0.00 0.00 0.02 0.08 0.09
Total 77.27 19.70 3.03 100.00 80.63 15.26 4.11 100.00
Interval cancers incidence Interval, y n Incidence n Incidence
per 1000 man-years 0–1 4 0.19 11.00 0.53
in interval since last screen 1–2 4 0.25 10.04 0.62
2–3 7 0.58 8.80 0.74
3–4 6 0.85 5.64 0.80
>4 2 0.91 2.92 1.33
Total 23 0.40 38.40 0.66
*Observed counts used for validation together with counts as predicted by the base model. For stage and grade distribution, only complete cases are shown. Results
from the European Randomized Study for Screening for Prostate Cancer (ERSPC) trial include all cases up to July 1, 2000. G  Gleason score.
†Data from the 1991 Netherlands Cancer Registry (29).
‡Data from the Rotterdam Cancer Registry for 1992 and 1993 (30).
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other programs, overdetection rates), we obtained ranges that
corresponded to approximate 95% CIs in the following way. The
profile likelihood approach generated a range of models, one of
which corresponded to the lower limit of the 95% CI for mean
lead time, and another that corresponded to the upper limit. We
used the predictions of these two models as approximate limits
of the 95% CIs for the other outputs. This procedure was justi-
fied by the close relation between the mentioned outputs (i.e.,
between lead time in the age 55–67 program and lead times in
other programs and/or overdetection rates).
RESULTS
ERSPC Trial Results
Table 1 summarizes trial results and baseline prostate cancer
incidence information. Prostate cancer detection rates were high
in both screening rounds of the trial: Approximately 54 cases
were detected per 1000 men (aged 55–75 years) in the first round
and approximately 40 cases were detected per 1000 men in the
second round. The first-round detection rate in the screened arm
was nearly 30 times the baseline incidence in the 55–75 year age
group (1.86 cases per 1000 man-years) and 17 times the inci-
dence in the control arm (3.18 cases per 1000 man-years). Pros-
tate cancer incidence in the control arm was 1.7 times the base-
line incidence. The number of interval cancers diagnosed (23)
was very small compared with the number of cancers detected in
the screened arm (1208) and the number of cancers diagnosed
in the control arm (221).
Screen-detected cancers had a more favorable stage distribu-
tion than those clinically diagnosed in the pre-screening era,
when 23% of the diagnosed cancers were distant-stage cancers
(see Table 1 and Fig. 3, A). In the trial, only 0.6% of the can-
cers detected in the first round of screening and none of the
cancers detected in the second round were metastatic. The per-
centage of localized cancers changed from 58% at baseline to
79% of cancers detected in the first round and 94% of cancers
detected in the second round of screening. The cancers diag-
nosed in the control arm had an intermediate distribution: 6.3%
were distant and 69% were localized.
Screen-detected cancers were also more well-differentiated
than clinically diagnosed cancers. For instance, only 8% of the
cancers detected in the first round of screening and 3% of those
detected in the second round were poorly differentiated (Gleason
score >7), compared with 22% of the cancers found in the con-
trol arm of the trial (Fig. 3, B). Gleason scores were not available
for cancers detected in the pre-screening era.
Goodness of Fit of Model Predictions
When fitted to both baseline and trial data, the basic model
accurately predicted the main characteristics of the data: the
baseline age-specific incidence (crude incidence  1.91 cases
per 1000 man-years predicted versus 1.86 cases observed in the
55–75 year age group; see also Fig. 4), the overall incidence in
the control arm (2.96 cases per 1000 man-years predicted versus
3.18 cases observed in the 55–75 year age group), and the over-
all detection rate in both the first (55.73% predicted versus
53.86% observed) and second screening rounds (37.84% pre-
dicted versus 40.42% observed) of the trial (Table 1). The tumor
stage and grade distributions predicted by the model were also
similar to the observed distributions. The estimated test sensi-
tivities in the model were 64%, 91%, and 98% for local, re-
gional, and distant cancers, respectively. In the model, the
difference between incidence in the control arm and baseline
incidence was the result of screening in the control arm at a rate
of 30 tests per 1000 man-years.
Fig. 2. The MISCAN model of the history of
prostate cancer up to clinical diagnosis. The
model distinguishes between cancer tumor–
node–metastasis (TNM) stages (normal, local-
ized [Loc: T1/2, N0/X, M0/X], regional [Reg:
T3/4 or N+ and M0/X], and distant [Dis: any
TN, M1]) and between differentiation grades
(G1: Gleason score <7; G2: Gleason score  7;
and G3: Gleason score >7). Screening may de-
tect cancer in one of the preclinical stages. The
course of events may be interrupted by death
from other causes. Key parameters of the basic
model, fitted to all data, are indicated in the dia-
gram. Transition probabilities are indicated next
to the arrows; mean dwelling times in years are
indicated in parentheses. Other parameters are
cumulative incidence (the probability of ever
getting prostate cancer) (0.19); Weibull shape
parameters for dwelling times in the normal
(10.7), localized (5.3), and regional or distant
stages (5.0); sensitivities of the screening test for
localized (0.64), regional (0.91), and distant
stages (0.97); and contamination (30 tests per
1000 man-years). Time of death by causes not
related to prostate cancer was obtained from the
standard male life table (Statistics Netherlands,
1991–1995).
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However, the basic model did not accurately predict age-
specific incidence and detection rates in the trial population. In
the control arm, observed incidence for the youngest age group
(55–60 years) was statistically significantly higher than that pre-
dicted by the model, whereas the observed incidence for the
oldest age group (75+ years) was statistically significantly lower
than predicted (Fig. 4). In addition, the observed detection rates
for the first round of screening were slightly higher in the young-
est age group (55–60 years) and lower in the oldest age group
(70–75 years) than those predicted by the model (Fig. 5). The
model also predicted more interval cancers than were observed,
especially in the 2-year period directly following screening (21
cancers predicted versus eight cancers observed). The overall
incidence of interval cancers predicted by the model was 0.66
per 1000 man-years; the observed incidence was 0.40 per 1000
man-years.
None of the alternative models performed better than the
basic model when fitted to all available data, i.e., baseline and
trial data. However, we could obtain a statistically acceptable fit
for all four models when fitting to the trial data only (Table 2).
Notably, the models predicted fewer (25–31) interval cancers in
this case. In general, chi-square values obtained for the basic and
latent-stage cancer models were similar and were substantially
lower than those obtained for the fixed-grade or exponential
models.
Lead Time and Overdetection in Prostate Cancer
Screening
Table 3 summarizes the predictions from the basic model of
mean lead time and rates of overdetection associated with vari-
ous screening programs. We assumed that each screening pro-
gram had 100% attendance. The lower and upper limits of the
ranges in the table are based on predictions of short and long
lead time variants of this model, respectively.
Fig. 3. Distribution of tumor stage and differentiation grade of cancers at clinical
diagnosis or detection as observed (left bar of each pair) and as predicted by the
basic model (right bar of each pair). A) Tumors were categorized as localized
(T1/2, N0/X, M0/X), regional (T3/4 or N+, M0/X), or distant (any TN, M1)
cancers. Shown are the baseline stage distribution [data obtained from the 1992–
1993 Rotterdam Cancer Registry (30)] and the stage distributions of cancers in
the control arm of screen-detected cancers from the first and second screening
rounds of the Rotterdam European Randomized Study of Screening for Prostate
Cancer trial. B) Shown are the Gleason score (G) distributions of cancers in the
control arm and of screen-detected cancers from the first and second screening
rounds of the Rotterdam European Randomized Study of Screening for Prostate
Cancer trial.
Fig. 4. Age-specific prostate cancer incidence rates in The Netherlands, accord-
ing to the 1991 Netherlands Cancer Registry [NCR; (29)], and in the control arm
of the Rotterdam section of the European Randomized Study of Screening for
Prostate Cancer trial as observed (obs), and as predicted by the basic model
(mod). In the model, opportunistic screening in the control arm occurs at a rate
of 3% per year. Model predictions are represented by solid symbols and con-
nected by lines. Vertical bars represent 95% prediction intervals. Correspond-
ing observed values are indicated by open symbols.
Fig. 5. Age-specific detection rates in the first and second screening rounds of
the Rotterdam European Randomized Study of Screening for Prostate Cancer
trial, as observed (obs) and as predicted by the basic model (mod). Model
predictions are represented by solid symbols and connected by lines. Vertical
bars represent 95% prediction intervals. Corresponding observed values are
indicated by open symbols.
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With a single screening test, the estimated mean lead time
decreased with screening age from 12.3 years (range  11.6–
14.1 years) at age 55 to 6.0 years (range  5.8–6.3 years) at age
75. The estimated mean lead times associated with screening
programs that have regular screening intervals ranged from 9.9
to 13.3 years. The estimated mean lead times associated with
annual screening were approximately 1 year longer than those
associated with 4-year interval screening. These lead-time esti-
mates apply to all cases, both relevant cases that would have
been diagnosed without screening and irrelevant cases that
would not. Mean lead-time estimates for relevant cases only
were slightly higher than they were for all cases: up to 0.5 year
longer in screening with a single test or 1–2 years longer in
interval screening.
The basic model predicted that the lifetime risk of developing
screen-detectable cancer was 151 per 1000 men (range = 145–
166 per 1000 men) (Table 3). Only 64 per 1000 men would be
clinically diagnosed with prostate cancer in the absence of
screening (relevant cases). To illustrate how overdetection is
calculated, consider screening with a single test at age 65. The
test was predicted to detect 28 relevant cases and 24 irrelevant
cases per 1000 men screened; thus, screening would detect 28 of
64 (44%) relevant cancers, overdetection would occur in 24 of
52 (47%) detected cases, and the lifetime risk of a cancer diag-
nosis would rise from 64 to 88 per 1000 men, an increase of
38%. With a single screening test at age 70, the largest fraction
of the clinically relevant cancers, 47% (30 of 64), would be
detected. However, the test would detect irrelevant cancers in 34
Table 2. Sensitivity analysis*
Source of data for fitting model Model
Fit
Lifetime risk per 1000 men Mean lead time, y Overdetection
Any cancer
Relevant
cancer All cases
Relevant
cases
% of
detection
% increase
in lifetime risk2† P‡
Trial + baseline Latent-stage 68.8 .006 153.5 63.7 10.9 11.6 47 62
Basic 63.0 .020 150.5 63.5 11.2 12.3 48 65
Exponential 126.4 .000 172.7 62.2 11.3 10.8 54 71
Fixed-grade 93.2 .000 167.8 63.3 11.4 11.9 51 70
Trial only Latent-stage 36.7 .702 149.8 52.1 12.2 9.5 59 93
Basic 37.5 .670 148.6 55.8 12.0 12.8 51 77
Exponential 44.1 .382 153.7 49.5 12.7 11.6 60 98
Fixed-grade 48.2 .237 147.7 51.6 12.3 11.7 57 92
*Estimates of lead times and overdetection rates in a screening program with a 4-year interval starting at age 55, as predicted by four different models. Each model
was fitted to baseline and trial data or to trial data only.
†As presented in Table 1, control arm and screened arm sections.
‡Calculated with 42 degrees of freedom.
Table 3. Predictions of mean lead time and overdetection rates associated with screening from the basic model*
Type of cancer
Any Relevant Irrelevant
Lifetime risk per 1000 men† 151‡ 64 87
(145 to 166)‡ (80 to 103)
Mean sojourn time§, y† 12.7 15.4 10.8
(range) (12.1–14.2) (10.0–12.5)
Screening program Age, y
Mean lead time, y (range) Detection per 1000 men Overdetection (range)
All cases
Relevant
cases
All
cases
Relevant
cases
Irrelevant
cases
% of
detection
% increase
lifetime risk
Single 55 12.3 (11.6–14.1) 12.8 (12.0–14.6) 15 11 4 27 (24–37) 6 (5–9)
60 11.0 (10.4–12.4) 11.5 (11.0–13.0) 31 19 12 38 (34–47) 18 (15–25)
65 9.5 (9.0–10.5) 10.0 (9.6–11.0) 52 28 24 47 (43–55) 38 (33–49)
70 7.7 (7.4–8.3) 8.1 (7.9–8.7) 64 30 34 53 (50–60) 54 (49–60)
75 6.0 (5.8–6.3) 6.2 (6.0–6.6) 54 24 30 56 (53–61) 47‡
Interval Every y, 55–67 12.3 (11.8–13.3) 13.7 (13.3–14.7) 103 52 51 50 (46–57) 80 (69–116)
Every y, 55–75 11.6 (11.1–12.6) 13.4 (13.0–14.4) 140 61 79 56 (54–61) 124 (111–153)
Every 4 y, 55–67 11.2 (10.8–12.1)‡ 12.3 (11.9–13.2) 87 45 41 48 (44–55) 65 (56–87)
Every 4 y, 55–75 10.3 (9.9–11.2) 11.7 (11.3–12.5) 123 57 66 54 (51–59) 105 (95–124)
*In the model, the indicated screening programs were applied to a hypothetical cohort of 1 million men, assuming 100% attendance. Detected cancers were
classified as relevant (i.e., those that would have been diagnosed in the absence of screening) or irrelevant (i.e., those that would not have been diagnosed in the
absence of screening). The rate of overdetection is expressed as a percentage of total detection and as the percent increase in the lifetime risk of a prostate cancer
diagnosis.
†Estimates refer to situation without screening.
‡Prediction from basic model and range supported by the data (approximate 95% confidence interval). Ranges are presented only for those predictions that have
a close relation to mean lead time in the 4-year interval, age 55–67, screening program, for which the range is a proper 95% confidence interval.
§Sojourn time  duration of the screen-detectable preclinical phase of the disease.
Lead time  time that diagnosis is advanced by screening.
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of 64 detected cases, corresponding to an overdetection rate of
53% (range = 50%–60%), increasing the lifetime risk of a cancer
diagnosis from 64 to 98 per 1000 men, an increase of 54%
(range = 49%–60%).
The model predicted that screening with a 4-year interval
from age 55 to 67 would detect 70% (45 of 64) of all clinically
relevant cancers. However, irrelevant cancers would be found in
41 per 1000 men; this number corresponds to an overdetection
rate of 48% (range  44%–55%) and an increase in the lifetime
prostate cancer risk from 64 to 106 per 1000, a relative increase
of 65% (range  56%–87%). Annual screening from age 55 to
67 was predicted to increase detection of relevant cancers to
81% (52 of 64), with an overdetection rate of 50% (range =
46%–57%) and an 80% increase in lifetime risk (range  69%–
116%). Extending interval screening programs to the age of 75
may detect up to 95% (61 of 64) of all clinically relevant can-
cers. However, such extensions would detect at least two irrel-
evant cancers for every relevant cancer, resulting, for annual
screening, in an overdetection rate of 56% (range = 54%–61%)
and a relative increase of 124% (range = 111%–153%) in the
lifetime risk of prostate cancer.
The alternative models, when fitted to both baseline and trial
data, predicted lead times and overdetection rates for the 4-year
interval screening program from age 55 to 67 that generally were
similar to the predictions from the basic model, i.e., within the
ranges presented in Table 3. By contrast, models fitted to trial
data only (Table 2) predicted 1-year-longer lead times (12.0–
12.7 years), 5% higher rates of overdetection (51%–60%), and a
larger increase in the lifetime risk of prostate cancer (77%–
98%).
DISCUSSION
Our results suggest that regular screening for prostate cancer
may advance diagnosis by at least 10 years. Approximately half
of the screen-detected cancers in our models would not have
been diagnosed in the absence of screening; in men screened
between age 70 and 75, two of three cancers detected by screen-
ing would not have been diagnosed without screening. The in-
troduction of screening would lead to a 60%–90% higher inci-
dence of prostate cancer. How valid are these estimates, and how
do they compare with other published estimates?
The basic model, fitted to baseline and trial data, reproduced
the essential characteristics of the observed data on clinical
incidence, detection rates, and tumor stage and Gleason score
distributions. Contamination (i.e., opportunistic screening
among men in the control group) could explain both the higher
cancer incidence and the more favorable stage distribution of
cancers in the control arm compared with those at baseline in the
pre-screening era. The model-estimated rate of contamination
(30 tests per 1000 man-years) was somewhat higher than the
estimate of 17–22 tests per 1000 man-years that was based on
the fraction of cases in the control arm among men who reported
having no symptoms before diagnosis (see Appendix).
However, observed incidence and detection rates in the older
age groups of the trial were statistically significantly lower than
predicted by the basic model (Figs. 4 and 5). In contrast, models
that were fitted to trial data only predicted lower incidence of
prostate cancer than was observed in the baseline population
registry data in these age groups. These results suggest a (self-)
selection effect in the older age groups (i.e., that the older par-
ticipants in the trial were healthier than average). Because the
participation rate in the trial was just under 50%, this possibility
cannot be ruled out.
Selection might also be responsible for the difference be-
tween observed (23) and predicted (38 in the basic model) num-
bers of interval cancers. Again, fitting to trial data only resulted
in lower predicted numbers of interval cancers in all models
(i.e, 25–31 interval cancers).
Data on the sensitivity of PSA screening in combination with
sextant biopsies are scarce. Probably the sensitivity is largely
determined by the biopsy part of the screening. For sextant bi-
opsies, a sensitivity of approximately 70% can be inferred from
the literature (32–34). In our models, estimated test sensitivities
ranged from 64% to 79% for localized cancer, from 77% to 94%
for regional cancer, and from 84% to 99% for distant cancers.
Because most screen-detected cancers are localized, our esti-
mates are compatible with the biopsy sensitivity estimates
above.
Our estimates are based on the 1991 data on prostate cancer
incidence in The Netherlands and on the results of the Rotterdam
section of the ERSPC. Consequently, our lead-time and overde-
tection estimates apply specifically to the 1991 situation in The
Netherlands with respect to clinical detection of prostate cancer
and to the screening test used in the Rotterdam section (PSA
level 3 ng/mL and a positive biopsy). The intensive screening
protocol, its changes over time, and the possibility of selection in
the trial population should also be kept in mind when general-
izing our results to other situations. Finally, our results apply to
screening programs with 100% attendance.
Other lead-time estimates have come from retrospective stud-
ies, in which blood samples were obtained from healthy men
who later developed clinical prostate cancer. For example, Gann
et al. (17) estimated a mean lead time of 5.5 years for prostate
cancer patients whose mean age at baseline was 63.9 years,
using a PSA test with a cutoff level of 4 ng/mL (366 cases).
Hugosson et al. (14) estimated a mean lead time for increased
PSA (i.e., PSA 3 ng/mL) of 7 years in a cohort of men who
were aged 67 years when their blood samples were collected in
1980 (52 cases). For prostate cancer patients who had PSA lev-
els between 3 and 10 ng/mL, the estimated mean lead time was
9.2 years (14). Stenman et al. (16) estimated that PSA levels
exceeded 4 ng/mL an average of 9.2 years before diagnosis
(44 cases). Pearson et al. (15,35) used serial PSA measurements
to estimate that PSA levels begin to increase exponentially ap-
proximately 7.3 years before diagnosis in men with localized or
regional cancers and 9.2 years before diagnosis in men with
metastatic distant cancers (18 cases in total). Our lead-time
estimates (i.e., 8–10 years for a single screening test at age 65
or 70) are higher than those of Gann et al. (17), comparable to
those of Hugosson et al. (14), Stenman et al. (16), and Pearson
et al. (15,35), and substantially higher than the 3-year lead time
used in analyses of the recent decline in prostate cancer mortality
following the introduction of PSA screening in the United States
(6).
Lead-time estimates from retrospective studies should be
used with caution for two reasons. First, they may be limited by
the length of the follow-up period in the study. For instance, our
basic model predicts that 40% of the lead times exceed 15 years
for a single test at age 67. Second, as illustrated in Table 3, mean
lead time varies with a man’s age at screening. Consequently,
estimates that are based on screening at age 65 or over cannot be
used to model screening at age 55.
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Our results on overdetection should be compared with the
results of Zappa et al. (21) and Etzioni et al. (22), who used the
same definition of overdetection that we did, i.e., the detection
of cancer that would not have been found in the absence of
screening. Zappa et al. (21) expressed overdetection as the rela-
tive increase in cancer incidence caused by screening. They
estimated the cumulative cancer incidence in a cohort of 10 000
men over a period of 10 years in a situation without screening
and with screening. For biennial screening programs with five
invitations, starting at age 60 or 65, their estimates of the relative
increase in cancer incidence were 25%–51% and 65%–93%,
respectively. Our estimates were based on a much larger number
of cancers (1452 versus 58) but were similar to their estimates.
However, when we applied their method for estimating overde-
tection to our data and used a screening program with a 4-year
interval (for men aged 55–67), we obtained a higher estimate of
overdetection: screening raised the lifetime risk of a prostate
cancer diagnosis by 107% (see Appendix).
Etzioni et al. (22) used a competing risk model to estimate
overdetection in the United States. In that model, the probability
of overdetection for a screen-detected case equals the probability
of dying of other causes during the lead time. For each age, this
probability can be obtained from the standard survival table,
assuming a suitable distribution function for lead time. Overall
overdetection can be calculated as a weighted sum of these
probabilities. Etzioni et al. used mean lead times of 3, 5, and
7 years to obtain estimated overdetection probabilities of 15%,
25%, and 35%, respectively. These estimates apply to screening
programs that use 4 ng/mL as the cutoff value for PSA. In their
model, only the 5-year lead time was compatible with U.S. in-
cidence trends. Our estimates of mean lead time are much higher
than those of Etzioni et al. and are associated with higher rates
of overdetection. The difference between these estimates is
probably related more to the bias in lead-time estimates referred
to above than to the lower cutoff value for PSA used in our trial
(3 ng/mL).
In conclusion, these lead-time estimates, which are the first to
be based on results of a large-scale screening trial for prostate
cancer in a population-based setting, support a screening interval
of more than 1 year. Screening for prostate cancer is likely to
advance diagnosis considerably and to be associated with con-
siderable overdetection. The net balance of favorable and unfa-
vorable effects of screening remains to be established.
APPENDIX
The MISCAN Model
The MISCAN program was designed at our institution and has been
used extensively for the analysis and surveillance of screening pro-
grams (24–26). In MISCAN, individual life histories are first simulated
in the absence of screening. A life history consists of a sequence of
states and the time spent in those states (dwelling times). These states
and times are generated by a semi-Markov process: at each step a next
state is generated with probabilities determined by the present state. The
distribution of the dwelling time in the present state is also determined
by the present state. Optionally, transition probabilities and dwelling
time distributions can be made age-dependent. Death from other causes
is generated independently using a standard life table.
Fig. 2 shows the states in the prostate cancer model up to the moment
of clinical detection. It specifies all relevant parameter values used in
the basic model: cumulative incidence (the probability of ever getting
cancer), transition probabilities and mean dwelling times, the Weibull
shape parameters that determine the variance of these dwelling times,
and the estimated test sensitivities. We used the Dutch male life table
(Statistics Netherlands, 1991–1995) for generating the time of death
from other causes of each individual.
Screening is superimposed on the life histories in the absence of
screening. Preclinical cancers may be detected by screening. Detection
depends on attendance and the sensitivity of the screening test for the
specific preclinical state. Attendance rates were obtained directly from
the trial database.
Parameter Estimation
All parameters shown in Fig. 2 were estimated from the data pre-
sented in Table 1 with the use of a model that included the trial popu-
lation characteristics (e.g., age distributions and attendance rates). For
each set of parameter values, the model generates life histories and
counts the cases in each of the categories in Table 1. These counts are
considered predictions from the model. Although the predictions are
random, increasing the sample size in the simulations reduces variance.
Parameters are estimated by minimizing the difference between ob-
served and predicted counts, measured as the sum of the chi-square
quantities using an adapted version of the simplex optimization method
of Nelder and Mead, as outlined in (36). Adaptations to the random
nature of the objective function are a shrinking value of 0.9 instead of
0.5 and recalculation of all function values at a simplex shrink step (37).
Optimization was initiated with small sample sizes (i.e., 10 000) and
repeated with larger sample sizes (i.e., up to 1 million) when optimi-
zation progress was no longer statistically significant. For all models,
we tried a number of different starting values and kept the best result.
Confidence Intervals
We used the basic model and a profile likelihood approach to obtain
a 95% CI for mean lead time in the 4-year interval screening program
for individuals aged 55–67 years. We used penalized optimization to
obtain a range of models with different lead times, each of them opti-
mized for the results in Table 1. The penalty added to the objective
function (sum of the chi-square values calculated from the difference
between observed and predicted numbers in Table 1) was the squared
difference between mean lead time predicted by the model and a target
lead time chosen from a range (8, 9, . . ., 14 years) of lead times. We
considered the sum of chi-square values to be a random variable from
a chi-square distribution with 53 degrees of freedom (the number of
independent cells) and used it to obtain a likelihood for each model lead
time. A 95% CI for mean lead time was calculated from the resulting
profile likelihood. The models that correspond to the lower and upper
limit of this CI were used to calculate ranges supported by the data for
lead time and rates of overdetection in the other programs.
Estimating Contamination
From the medical files of the men in the control arm who were
diagnosed with prostate cancer, we found that 30% did not have symp-
toms before diagnosis. Therefore, we assumed that they had been di-
agnosed because of opportunistic screening. Assuming further that the
sensitivity of screening in the control arm equaled the sensitivity in the
screened arm, we calculated the rate of testing using the formula: test
rate  0.3 × (control arm incidence/screened arm detection rate)  0.3
× (3.18/53.9) or 0.3 × (3.18/40.4)  17 or 23 tests per 1000 man-years,
depending on whether first-round or second-round detection rates were
used. This test rate was less than the rate of 71 PSA tests per 1000 man-
years reported in the control arm of the Rotterdam trial, because the
latter rate also included diagnostic PSA tests. No direct estimate of
the proportion of PSA tests used for screening purposes was available
from the data (31).
Estimating Overdetection by the Method of Zappa et al.
(21)
The probability of a man getting prostate cancer at age t can be
approximated by the product of the age-dependent cancer incidence I(t)
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and the probability of still being alive at age t, the standard survival
function S(t). The lifetime risk of getting a cancer diagnosis is approxi-
mated by the sum of the products I(t) × S(t) for all ages t. We used the
data of The Netherlands Cancer Registry for 1991 and the male Dutch
life table to calculate this risk, which was 68 cases in 1000 men. For
screening at age 55, 59, 63, and 67 years, we assumed detection rates of
28 cases per 1000 men in the first screen (the observed first-round
detection at age 55 in Table 1), and 33, 43, and 53 cases per 1000 men
(the observed second-round detection rates in Table 1) in the following
screens. Interval cancers appear at a rate of 0.4 cases per 1000 man-
years (also from Table 1) in each year up to the age of 70. Thereafter
we assumed that incidence returned to the normal age-dependent level
of eight cases per 1000 man-years at age 85. Multiplying as before the
number of cases detected or clinically diagnosed per 1000 men at age
t with the probability, S(t), of being alive and adding the products
resulted in a total of 141 prostate cancer cases per 1000 men. Thus,
screening would raise incidence by 107% (141/68–1). This estimate is
higher than our model-based estimates of 62%–93% (Table 3). The
difference may relate to the assumption that all repeat screenings would
have the same detection rate as the second round did.
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